MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.
Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance IP Portfolio
Champignon Brands has added a new contact research organization (CRO) to advance its IP portfolio.
Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans Launch of Initial Medicinal Mushroom Based Product Line
AlphaMind Brands Inc is entering the functional mushrooms market.
MindMed Launches Project Lucy Focused On LSD Experiential Therapy For Anxiety Disorders
MindMed has high hopes for its new LSD-based anxiety therapy.
Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director
Numinus adds to its management team.
MindMed Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
MindMed's Microdosing Division is expanding its ADHD clinical trial.
Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing
Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.
Numinus Announces 2020 Operational Plans to Scale
Newly-listed Numinus Wellness provides a corporate update.
MindMed Adds MDMA for Development of Next-Gen Psychedelic Therapies
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
Psychedelic Drug Therapy: Laying Out The Picture
Psychedelic drug proponents have touted some very exciting clinical studies. Investors will want to look past the headlines and take a closer look at these drug therapies.
Dr. Gabor Maté joins Numinus as Member of the Clinical Advisory Council
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.
MindMed Closes on Upsized Financing of $13.2m
MindMed has issued 24.95 million units at a unit price of CAD$0.53.
